Company ProfilePremium

Oxurion NV

Company Profile Analysis

Ticker: OXUR.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Oxurion NV - Company showcase

Year Founded & Workforce

1991

Oxurion NV logo

Oxurion NV Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Oxurion NV Overview

Oxurion is the shell of a former Belgian ophthalmology biotech. It has been repurposed into a listed vehicle that acquires majority stakes in small European CROs. The heritage is substantial. As ThromboGenics, the company created the pharmacological vitreolysis category with JETREA (ocriplasmin), which was approved in 54 countries. After its last clinical asset, THR-149, failed in November 2023, the company avoided bankruptcy only through a rescue agreement with its convertible-bond investor, Atlas Special Opportunities. It then went through a court-supervised private reorganisation in 2024 and stopped all internal R&D in August 2025. Today its only operating asset is a 72% stake in Axiodis CRO, a Toulouse biometrics and clinical-data-management specialist with about €1.0 million in revenue. Axiodis owns the Exagis CDMS platform. Oxurion is pursuing a buy-and-build strategy: an international CRO LOI (March 2026) and exclusive talks on Eclevar, a MedTech CRO (September 2026). Equity is negative, cash is close to zero, and funding depends entirely on conditional Atlas convertible tranches.


Company's own description (latest filings)

The FY2025 Annual Report describes Oxurion as moving from a pure biopharmaceutical R&D model to an integrated European platform of clinical research services. It plans to get there by acquiring majority stakes in promising pharmaceutical subcontractors (CROs). The stated aim is to improve clinical development through clinical data management, biometrics, eClinical technologies (eCRF), regulatory affairs and statistical analysis.

The H1 2026 Interim Report describes the group as a "technology-enabled European clinical research group." It combines specialised CRO services, proprietary software (Exagis) and external growth. The client focus is pharmaceutical, biotechnology and medical-device sponsors, with emphasis on clinical data, biometrics and eClinical technologies. Press releases from October 2026 describe the company as building a technology-enabled clinical research and software platform.

Independent characterisation

Oxurion is in practice a micro-cap listed holding company with three characteristics:

  1. One small operating subsidiary (Axiodis CRO). Axiodis generated about €1.0 million of operating income in calendar 2025 and has been profitable at the net level since inception.

  2. A holding-company cost base larger than the subsidiary's revenue. This covers listing, reporting, M&A and legacy liabilities. Group G&A was €2.3 million in FY2025 against €0.6 million of consolidated revenue.

  3. A financing structure dominated by one investor, Atlas Special Opportunities II LLC. Atlas is at once a convertible bondholder, lender, second-ranking pledgee and, intermittently, the largest shareholder. The FY2025 Annual Report states that Atlas is presumed to have de facto control under Article 1:14 of the Belgian Code of Companies and Associations (BCCA).

Business and revenue model

DimensionCurrent model (FY2025–H1 2026)Legacy model (to FY2023)
Core activityOutsourced clinical biometrics: data management, biostatistics, statistical programming, eCRF/CDMSOphthalmic drug R&D (DME, AMD, GA); JETREA commercialisation
Revenue typeService fees per study mandate (project-based contracts); platform use embedded in servicesProduct sales (JETREA vials) and royalties
Product vs service vs licensing mix~100% services (FY2025: €555k; H1 2026: €591k)FY2023: product sales €0.2M, royalties €0.1M (statutory)
Subscription / SaaSNot reported separately. Exagis is being productised as a broader eClinical suite (roadmap)—
Value-chain positionTier-3 specialist / functional service provider. Works directly for sponsors and as subcontractor to full-service CROs (e.g., the KYomed INNOV & CEISO partnership)Drug originator / licensor
CustomersPharma, biotech, medtech and academic sponsors. About 10 clients; top 3 ≈ 80% of revenue; largest ≈ 50% (Source: AR FY2025, risk 3.5.2.1)Ophthalmologists via distributors (Inceptua, Alcon, earlier Novartis)
End-marketsClinical development services (drugs and medical devices); new focus offerings in GLP-1, peptides and biosimilars (June 2026)Retinal disease therapeutics
GeographyFrance-based delivery; operational footprint in "more than a dozen countries" (H1 2026 report)Global

Contracting model

Axiodis typically signs individual service agreements per trial rather than long-term framework contracts (AR FY2025). It must therefore keep winning new mandates. Revenue visibility is short, and there is no disclosed backlog.

Strategy

Stated strategy (themes from AR FY2025 and H1 2026)

Vision: management's stated ambition is to become a leading European player in pharmaceutical outsourcing, centred on clinical data.

Platform strategy: integrate Axiodis's eCRF, data-management and biometrics capabilities with complementary regulatory, eClinical and statistical expertise into one clinical-data platform.

Execution focus: move capital and headcount from internal R&D to CRO operations and technology, funded by Atlas.

Profitability and selectivity: target profitable acquisitions with differentiated capabilities, growth prospects and a direct fit with the data platform.

"One-stop shop": cover the clinical development continuum from trial design to market access.

Technology: use Exagis as the common backbone and expand it into an eClinical suite (randomisation, supply, analytics, AI-assisted tools).

Initiatives (last 24 months)

DateInitiativeStatusTarget / metricSource
Jul 2024 – Apr 2025Acquisition of a majority stake in a French stem-cell / beta-cell CROTerminated 25 Apr 2025 (target's results came in better than expected, so terms were not agreed)—PR 25 Apr 2025
Aug–Nov 2024Private judicial reorganisation (debt restructuring)CompletedDebt cut from €14.7M to €11.2MPRs Sep and Nov 2024
Mar–Aug 2025Axiodis CRO acquisition (72%)Completed 1 Aug 2025Axiodis targets >€2M revenue and 20% EBITDA by 2027PRs 16 May and 4 Aug 2025
Jul 2025 – Jan 2026Treasury diversification into Bitcoin/Ethereum (€10M, then €30M Atlas convertible facility)Suspended 19 Jan 2026—PRs 22 Jul 2025, 4 Aug 2025, 19 Jan 2026
7 Aug 2025Termination of all internal R&DCompletedCost rationalisationAR FY2025
Oct 2025 – Jun 2026LOI for 80% of a French CRO (clinical development and regulatory affairs)Terminated 1 Jun 2026 after due diligence—PRs 13 Oct 2025, 1 Jun 2026
16 Feb 2026Axiodis sales and marketing accelerationOngoingBroaden beyond its regional basePR 16 Feb 2026; H1 2026
10 Mar 2026Fourth amendment to the Atlas funding programmeIn force to 2 Mar 2027Monthly tranches of 12 convertible bondsAR FY2025
19 Mar 2026LOI for 75% of an international CRO (Europe, North Africa, Middle East)Pending / unconfirmedTarget 2025 EBITDA ≈ 20%PR 19 Mar 2026
2 Jun 2026GLP-1 / peptide / biosimilar clinical-research offeringLaunchedMarket >$150B by 2029 (company-cited forecasts)PR 2 Jun 2026
21 Jul 2026Axiodis–KYomed INNOV & CEISO biometrics partnershipSigned≈ €110k annual revenue, up to €170kPR 21 Jul 2026
30 Sep 2026Eclevar MedTech CRO business acquisition (68% NewCo)Exclusive negotiationsClose by 31 Dec 2026; Eclevar targets ≈ €3M FY2027 revenuePR 30 Sep 2026

Medium-term targets and guidance

Group: no formal revenue, EBITDA or margin guidance.

Subsidiary/target ambitions (not group guidance): - Axiodis: >€2M revenue and 20% EBITDA by 2027.

  • Eclevar: ≈ €3M revenue in FY2027.

Funding: management states it must complete further acquisitions before 2 March 2027 to secure the company's survival (AR FY2025 §3.5.1.1).

ESG / sustainability commitments: none quantified.

Products & Services

Current portfolio (CRO platform)

OfferingDescription / capabilitiesTarget customerLaunch / versionPricing modelSource
Clinical Data Management (Axiodis)Full data cycle: protocol and methodology support, database design, data capture, cleaning, validation, query management, audit-ready documentationPharma, biotech, medtech and academic sponsorsAxiodis founded 2022 (first FY 1 Aug 2022 – 31 May 2023)Per-study service fees (not disclosed in detail)AR FY2025; H1 2026
BiostatisticsStatistical modelling and analysis plans, analysis execution, regulatory reporting for EMA/FDA submissionsSame2022–Per-studyPR 16 May 2025
Statistical programming / CDISCAdvanced command of CDISC standards (SDTM-aligned data structures)Same2022–Per-studyPR 16 May 2025; H1 2026
Project managementCoordination of biometrics deliverables, with a network of partnersSame2022–Per-studyH1 2026
Exagis CDMS (proprietary)Live clinical data management system built by clinical research professionals and already used in operational studies. Modular: eCRF data capture, query workflows, ePRO, eConsent, SDTM-aligned data structure, HDS-compliant secure hostingSponsors using Axiodis; positioned as the group's common technology backboneIn operational use. Roadmap: randomisation, clinical supply workflows, advanced analytics, selective AI-assisted toolsEmbedded in service fees; standalone licensing n/dH1 2026 Interim Report
Biometrics subcontracting for CROsSpecialist biometrics delivered to full-service CROs that lack in-house capacity (first reference client: KYomed INNOV & CEISO)Clinical CROs (medtech and digital-health focus)Jul 2026Expected about €110k annual revenue, potentially up to €170k (FinanzWire summary of PR)PR 21 Jul 2026
GLP-1 / peptide / biosimilar clinical-research offeringBiometrics, CDM, biostatistics and regulatory-grade data flows tailored to peptide-based programmesDevelopers of GLP-1, peptide and biosimilar drugsLaunched 2 Jun 2026—PR 2 Jun 2026

Prospective portfolio (pending transactions; unconfirmed)

Prospective offeringDescriptionStatusSource
Clinical operations / monitoring (international CRO)Multi-country operational CRO in Europe, North Africa and the Middle East; 2025 EBITDA margin expected around 20%LOI of 19 Mar 2026; exclusivity to 30 Jun 2026 (extendable). Status after June 2026 not confirmed in retrieved disclosuresPR 19 Mar 2026
MedTech CRO services (Eclevar)Pre-market clinical investigations, post-market clinical follow-up, regulatory advisory, global study design, EU market access; footprint in Europe, Japan and ChinaExclusive negotiations; target close by 31 Dec 2026PR 30 Sep 2026

Legacy / discontinued portfolio (historical record)

AssetDescriptionStatus
JETREA (ocriplasmin)Recombinant plasmin derivative for vitreomacular adhesion/traction (pharmacological vitreolysis); approved in 54 countriesLicensed to Inceptua (2020); commercialisation ended 31 Dec 2023
THR-149Bicyclic peptide plasma kallikrein inhibitor (licensed from Bicycle Therapeutics) for DME patients who respond suboptimally to anti-VEGFFailed KALAHARI Part B (Nov 2023); development halted
THR-687Pan-RGD integrin antagonist (Galapagos-derived) for DME / wet AMDNot advanced to Phase 2 Part B (2022); intangible disposed 31 Dec 2024
THR-317Anti-PlGF antibody, studied in combination with ranibizumab for DMEDiscontinued (pre-2021)
TB-403 / immuno-oncology (Oncurious)Anti-PlGF oncology programme; CCR8 and other I-O targetsImpaired 2021; CCR8 assigned to VIB in 2022 with a revenue-sharing right for Oxurion
GA CRISPR target-discovery platformGenome-wide CRISPR screening in a "patient in a dish" GA modelTerminated 7 Aug 2025

Financial Narrative

All figures are IFRS consolidated and in EUR thousands unless the row label says otherwise. Sources: AR FY2021 (FY2021), AR FY2023 (FY2022–FY2023), AR FY2025 (FY2024–FY2025).

Income statement

Notes:

  • Selling expenses for FY2024–FY2025 were none in the H1 2025 and H1 2026 interim P&Ls; the full-year FY2024 figure is inferred from the absence of a selling line in AR FY2025 commentary.

  • EPS for FY2021–FY2023 is on a pre-reverse-split basis. FY2024–FY2025 is post-split (1:10,000), so EPS is not comparable across the break.

EBITDA: n/d. An aggregator (Google Finance) shows FY2023 EBITDA of −€2.46M, which conflicts with the reported operating loss of −€12.1M and is not relied on.

Margins and growth (analyst calculations)

  • Revenue CAGR FY2021–FY2025 is −16.2% per year (analyst calculation).

  • Margins are mathematically derived but n/m economically, because of the tiny revenue base and the business-model change.

  • FY2025 gross profit (€0.6M rounded) slightly exceeds rounded revenue (€0.555M), which reflects rounding in the source. The H1 2026 gross margin is 98.8% (584/591).

Commentary. The P&L shows three regimes.

FY2021–FY2023 (clinical-stage burn): Operating losses of €12–28M a year were driven by the KALAHARI and INTEGRAL Phase 2 programmes. R&D fell from €20.7M to €10.0M as programmes were cut.

FY2022–FY2023 finance costs: Finance expense spiked (€9.4M and €7.3M), driven by fair-value and other charges on the Negma, Kreos/Pontifax and Atlas convertible instruments.

FY2024 (restructuring): Oxurion posted a rare positive operating result (+€0.4M) and net profit (+€0.1M). This was not operational. It came from €4.1M of other operating income, consistent with creditor write-downs and settlement gains in the judicial reorganisation, plus vendor settlements of about €1.0M (statutory).

FY2025 (pivot): Axiodis was consolidated for five months (€555k revenue). The holding-company cost base, including R&D up to the August termination, produced a €3.3M operating loss.

Interim trend (H1 2026 vs H1 2025)

Source: H1 2026 Interim Report.

Analyst note: H1 2026 still carries €0.74M of "R&D expenses," although all R&D was terminated in August 2025. This most plausibly reflects Exagis software development and Axiodis technical staff costs classified as R&D. The classification is not explained in the interim report.

Balance sheet

Debt split: convertible loans are classified as current in FY2025 (€11.3M) and H1 2026 (€11.4M). Lease liabilities are €48k non-current and €81k current at 30 Jun 2026. Total debt in H1 2026 is about €11.5M, all effectively short-term.

H1 2026 balance sheet: total assets €3,435k; cash €31k; equity −€13,294k; current liabilities €16,393k, including trade payables of €2,848k.

Commentary. The balance sheet is deeply insolvent on a book basis. Equity has been negative since FY2021, and net assets have been below the €61,500 statutory minimum since 27 March 2025, which exposes the company to dissolution claims under BCCA art. 7:229. The convertible-loan stack (about €11.3M, mostly Atlas and the assigned former Kreos/Pontifax facility) is roughly 3× total assets. The largest remaining non-cash asset is the Belgian R&D tax credit receivable (€1.17M non-current plus €0.99M current at YE2025). Management explicitly relies on this receivable to bridge its funding gap.

Cash flow

  • A secondary aggregator (Stoxray) shows −€27.2M (FY2021), −€20.0M (FY2022) and −€9.8M (FY2023). Google Finance shows −€1.43M for FY2023, a material conflict.

Free cash flow: n/m. It was approximately equal to operating cash flow, since capex was negligible (≤€0.06M a year).

Interim operating cash flow: −€1,128k (H1 2025) and −€573k (H1 2026).

Ratios (analyst calculations)

The following ratios are n/m in all years:

ROE: equity is negative in every year.

ROIC: invested capital is negative or undefined.

Debt/equity: equity is negative.

Net debt/EBITDA: EBITDA is negative or undisclosed.

Interest coverage: operating income is negative except in FY2024.

Cash conversion cycle: n/d.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment

Activity (EUR K)FY2021FY2022FY2023FY2024FY2025

JETREA-related income (vials and royalties)

1,12859526330

CRO services (Axiodis, consolidated from 1 Aug 2025)

0000555

Total consolidated income

1,1285952633555

Revenue by Segment

Legacy product split, statutory (EUR Mn)FY2021FY2022FY2023

Product sales (JETREA vials)

1.10.40.2

Royalties

0.20.20.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Total revenue (EUR K)

2633555

YoY revenue growth (%)

-55.8-98.918,400

CRO services share of revenue (%)

00100

Group Entities

EntityJurisdictionOwnershipFunction / status

Oxurion NV

Leuven, Belgium

Listed parent

Holding company, listing, M&A

Axiodis CRO SAS

Toulouse, France

72% (28% founders/employees, with a put option exercisable from 2029)

Sole operating subsidiary: biometrics, CDM, Exagis eCRF/CDMS

Oxurion France SAS

Toulouse, France

100%

Non-operational acquisition holding company (created 24 Dec 2024); lends to Axiodis via a shareholder loan

ThromboGenics, Inc.

New York, USA

100%

Legacy US subsidiary; dormant

Oncurious NV

Leuven, Belgium

100%

Legacy oncology subsidiary; assets impaired/assigned; dormant

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue / income (EUR K)

1,1285952633555

Gross profit (EUR Mn)

0.50.10.1-0.040.6

R&D expenses (EUR Mn)

20.716.010.01.41.8

Selling expenses (EUR Mn)

1.30.90.100

G&A expenses (EUR Mn)

7.26.03.72.32.3

Other operating income (EUR Mn)

1.20.81.74.10.4

Operating result (EUR K)

-28,495-22,946-12,110382-3,291

Finance income (EUR K)

171639414323360

Finance expense (EUR K)

-1,268-9,379-7,270-583-767

Pre-tax result (EUR K)

-29,592-31,686-18,966122-3,698

Net result (EUR K)

-29,595-31,693-18,969119-3,708

Basic EPS (EUR)

-0.77-0.37-0.010.09-0.13

Diluted EPS (EUR)

-0.77-0.37-0.010.00-0.13

Dividends per share (EUR)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

44.316.838.0-1,333108.1

Operating margin (%)

-2,526-3,856-4,60512,733-593

Net margin (%)

-2,624-5,327-7,2133,967-668

Revenue YoY growth (%)

-45.7-47.3-55.8-98.918,400

Cash Flow

Metric (EUR K)H1 2025H1 2026

Sales

0591

Gross profit

0584

R&D expenses

-705-740

G&A expenses

-1,178-868

Other operating income

92269

Operating result

-1,794-755

Finance income

6020

Finance expense

5-142

Net result

-1,187-904

Net result attributable to equity holders

-1,187-918

Non-controlling interest

014

Operating cash flow

-1,128-573

Financing cash flow

570175

Balance Sheet

Metric (EUR K)FY2021FY2022FY2023FY2024FY2025

Total assets

18,87611,9936,5505,6953,825

Cash and cash equivalents

9,7403,4961,624455430

Current investments

247955000

Goodwill

0000182

Intangible assets

1,000000483

Non-current R&D tax credit

4,0003,7853,5252,0301,169

Trade and other receivables

2,5173,3218782,385384

Total equity

-1,108-4,583-13,186-11,058-12,689

Non-current liabilities

9,0714,227129130336

Current liabilities

10,91312,34919,60716,62316,178

Convertible loans (EUR Mn)

11.87.012.011.211.3

Working capital (current assets − current liabilities)

2,496-5,243-16,867-13,038-14,371

Net debt (convertible loans − cash & investments; EUR Mn)

1.83.410.310.710.9

Cash Flow (Annual)

Metric (EUR K)FY2021FY2022FY2023FY2024FY2025

Capex (statutory investments)

2060000

Dividends paid

00000

Share buybacks

00000

Year-end cash incl. investments (EUR Mn)

10.03.61.70.50.4

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROA (net result / total assets, %)

-156.8-264.3-289.62.1-96.9

Current ratio (x)

1.230.580.140.220.11

Asset turnover (revenue / total assets, x)

0.060.050.040.000.15

Disclosure Point Details

Disclosure pointFigureSource

Atlas programme total commitment

€20.0M (conditional)

AR FY2023

Drawn by 31 Dec 2023

€11.5M

AR FY2023

Drawn by 31 Dec 2025

€16.35M (€3.65M remaining)

AR FY2025

Drawn by 30 Jun 2026

€16.65M (€3.35M remaining)

H1 2026

Actual Atlas receipts in 2025 vs plan

€1.75M received vs €3.6M planned

AR FY2025

Monthly cash need

≈ €0.32–0.35M

AR FY2025; H1 2026

Shortfall to Oct 2027 (absent funding)

≈ €3.9M

H1 2026

Cash on 14 Apr 2026

≈ €11k

AR FY2025

Funding horizon

Atlas funding ends 2 Mar 2027; no financing in place after that date

AR FY2025

Revenue by Region

Region (EUR K)FY2021FY2022FY2023FY2024FY2025

Belgium

1,12859526330

France

0000555

Region growth (%)

Region growth (%)FY2023FY2024FY2025

Belgium

-55.8-98.9-100

France

00100

Capital Markets

IndicatorValueSource

Last price (16 Oct 2026)

€0.0008

MarketScreener

5-day change

-33.33%

MarketScreener

Year-to-date change (2026)

-88.89%

MarketScreener

≈ 1-year change

≈ -94.8%

MarketScreener (column interpretation)

3-year / 5-year change

≈ -99.99% (also affected by the 1:10,000 reverse split and conversion dilution)

MarketScreener

2025 high

€0.1001 (17 Apr 2025)

AR FY2025

2026 reference points

€0.0042 (14 Apr 2026); €0.0026 (2 Jun 2026); €0.0014 (30 Sep 2026)

AR FY2025; ABC Bourse

Post-split reference

≈ €0.30, market cap ≈ €0.58M (29 Oct 2024)

Craft.co (secondary)

Share count (millions; post-split basis unless noted)

Sep 2024

Dec 2025

Shares outstanding

1.3462.60

Valuation Multiples

MultipleOxurionBasis

Market cap (EUR Mn)

0.19

232.0M × €0.0008

Enterprise value (EUR Mn)

≈ 11.5

Market cap + €11.38M convertible loans + €0.13M leases − €0.03M cash (30 Jun 2026)

EV / LTM sales (x)

≈ 10.0

LTM sales ≈ €1.15M (FY2025 €555k + H1 2026 €591k − H1 2025 €0)

P/E

n/m

Loss-making

EV / EBITDA

n/m

EBITDA negative / n/d

P/B

n/m

Negative book equity

Capital Instruments

InstrumentAmountMaturity / terms

Atlas convertible bonds (outstanding, unconverted)

Included in €11.38M convertible loans (30 Jun 2026)

Mandatory convertibles. Default interest of 20% p.a. on an Event of Default

Former Kreos/Pontifax loan (assigned to Atlas)

Included above

Repayment extended to 31 May 2027

Lease liabilities

€129k

€81k current; €48k non-current

Security

Second-ranking pledge on all movable business assets (up to €8.5M under the 2023 terms)

—

Analyst Conclusions

Management guidance

There is no formal group guidance. Management's qualitative outlook (AR FY2025 CEO letter; H1 2026 report) for 2026 calls for:

  • full integration of the technology capabilities;

  • completion of the "next strategic move";

  • acceleration of international expansion.

Subsidiary and target ambitions are Axiodis >€2M revenue and 20% EBITDA by 2027, and Eclevar ≈ €3M revenue in FY2027.

Consensus

There is no sell-side consensus.

Bull case

  1. Accretive, near-free acquisitions. If both pending deals close, pro forma revenue could plausibly approach €5M or more. The inputs are Axiodis ≈ €1.0M, Eclevar ≈ €2.5M normalised, and an international CRO valued at ≈ €3.7M on a 100% basis at roughly 20% EBITDA. Oxurion would pay almost no upfront cash, deferring payment through EBITDA- or revenue-linked puts.

  2. Operating leverage. The H1 2026 gross margin of 98.8% and an operating loss that narrowed from €1.79M to €0.76M year on year show the cost base is now small. Modest revenue scale could reach operating break-even.

  3. Structural tailwinds. Biometrics outsourcing (≈ 7–8% CAGR), EU MDR-driven medtech evidence demand and GLP-1/biosimilar trial volumes all favour small, specialised data-centric CROs that full-service CROs subcontract to (the KYomed model).

Bear case

  1. Insolvency arithmetic. Cash is €31k, equity is −€13.3M and convertible debt is €11.4M. Atlas funding expires on 2 March 2027 and depends on market-cap and liquidity thresholds the stock barely meets. The company itself states its going concern is "permanently threatened."

  2. Value capture goes to creditors, not shareholders. Shares outstanding rose about 2.6× in seven months of 2026. Management explicitly calls recovery prospects for existing shareholders "remote." Any enterprise value created is likely to accrue to Atlas through conversions.

  3. Execution record. Two acquisition processes have been terminated and one remains unconfirmed. The crypto-treasury plan was announced and then suspended. AGMs have been postponed twice. Management has never run a CRO. Axiodis's top client is about 50% of revenue.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
Signing and closing of Eclevar definitive agreementsBy 31 Dec 2026 (target)
Status update on the international CRO LOI (exclusivity lapsed 30 Jun 2026 unless extended)Undated
Monthly Atlas tranche drawdowns and conversion pace (denominator notices)Monthly
Any dissolution petition under BCCA art. 7:229, or an Atlas Event-of-Default noticeOngoing
FY2026 annual report and audit opinion≈ April 2027
New financing to replace Atlas after 2 March 2027Before March 2027
Axiodis client wins and diversification (KYomed-type partnerships; GLP-1 mandates)Ongoing
Former Kreos/Pontifax loan repayment deadline31 May 2027

Analyst verdict

Oxurion NV is no longer the company its identifiers suggest. The ophthalmology biotech that brought JETREA to 54 countries effectively ended with the THR-149 failure in November 2023. The listed entity today is a distressed micro-cap holding company with a market value of roughly €0.2 million. Its only operating asset is a 72% stake in Axiodis CRO, a well-run but tiny Toulouse biometrics business: about €1.0 million in revenue, profitable, and with a proprietary CDMS.

The strategic logic is coherent. Buying small European CROs at low multiples with deferred, performance-based consideration, and linking them through a shared eClinical platform, is a recognised roll-up model in a fragmented, growing market. The H1 2026 numbers show the first consolidated CRO revenue (€591k) and a much smaller operating loss.

But the capital structure dominates the investment case. Negative equity of €13.3 million, €11.4 million of convertible debt held by the same investor that converts and sells shares continuously, cash of €31k, and a funding programme that ends on 2 March 2027 together mean that equity holders sit behind a creditor with presumed de facto control. Net assets have been below the statutory minimum since March 2025. The auditor has flagged material going-concern uncertainty for three consecutive years. M&A execution has been inconsistent, and management has never operated a CRO.

For institutional purposes we classify Oxurion as uninvestable equity / special situation. The business has option value tied to closing Eclevar and the international CRO and to securing non-Atlas financing before March 2027. However, the dilution mechanics make it unlikely that existing shareholders capture that value, as the company itself acknowledges. Relevant counterparties (sponsors, target vendors and creditors) should treat Oxurion as a high-counterparty-risk entity and focus diligence on Axiodis on a standalone basis. The key signals to monitor are the next denominator notices and any Atlas default notice.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundAgeCompensation

Pascal Ghoson (via MARS SARL)

CEO & CFO; Executive Director

Since 28 Dec 2023

Previously Administrative & Financial Director of SA Energisme from May 2023 (Simply Wall St, secondary). Education n/d

37 (Zonebourse, secondary)

FY2024 total ≈ €280k, of which ≈ €270k salary (Simply Wall St, secondary). FY2025: fixed fee plus a one-off discretionary bonus approved by the board (amount n/d in retrieved extract; AR FY2025 §4.2)

Andy De Deene

Corporate officer / Chief Development Officer (legacy)

Since 2008 per Zonebourse

Legacy development function

——

Axiodis CRO management (CEO name n/d)

Subsidiary management

Retained post-acquisition

Founders retain 28% of Axiodis

——

Board of Directors

NameRoleIndependenceSinceBackground

Charles Paris de Bollardière

Chair, Non-Executive Director

Non-executive; Atlas proposed the December 2023 co-optees

28 Dec 2023

n/d in retrieved sources

Pascal Ghoson

CEO & CFO, Executive Director

Executive

28 Dec 2023

See above

James Hartmann

Independent Non-Executive Director

Independent (per company)

28 Dec 2023

Age 60 (Zonebourse)

Nelly Souleymane

Independent Non-Executive Director

Independent

Co-opted from 13 Jan 2025 (announced 14 Feb 2025)

About 19 years in corporate communications, reputation management and public affairs, a significant part at Bayer

Board & Management Changes

DateChangeContext

May 2021

Tom Graney appointed CEO (joined Oct 2020)

Graney-era clinical focus

28 Dec 2023

Board and management replaced. Pascal Ghoson CEO; Charles Paris de Bollardière Chair; James Hartmann director

Atlas rescue after KALAHARI failure

2023

Settlement agreements with former board members (non-recurring income ≈ €0.5M, statutory)

AR FY2023

13 Jan 2025

Anat Loewenstein and Nathalie Laarakker depart; Nelly Souleymane co-opted

PR 14 Feb 2025

Major Shareholders

HolderShares% of outstandingAs ofSource

Atlas Special Opportunities II LLC

55,555,555

≈ 23.9 (crossed above 20%)

9 Oct 2026

Transparency notice, 14 Oct 2026

Atlas Special Opportunities II LLC (earlier reference)

18,592,91820.96

17 Mar 2026

AR FY2025

Atlas Special Opportunities II LLC (earlier reference)

8,573,3329.67

29 Apr 2026

Whiteford Research (secondary)

Market Wizards B.V.

5,304,604

< 3 (crossed below)

8 Oct 2026

Transparency notice, 12 Oct 2026

UBS Group AG

—

Transparency notification filed

Sep 2025

Euronext press-release list

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeScale indicatorRelative positioning vs Oxurion/Axiodis

Full-service global CRO

IQVIA (US)

Tier-1 CRO

≈ $15B revenue (CCRPS 2025 directory, secondary); largest CRO services share in 2023 (MarketsandMarkets)

Several thousand times larger; also a potential client channel

Full-service global CRO

ICON plc (Ireland)

Tier-1 CRO

≈ $6.5B revenue (CCRPS, secondary)

Dominant; owns PRA Health Sciences

Full-service global CRO

Thermo Fisher (PPD) (US)

Tier-1 CRO

n/d here

Dominant

Full-service global CRO

Labcorp / Fortrea (US)

Tier-1 CRO

n/d (secondary figures unreliable)

Dominant

Full-service global CRO

Medpace, Parexel, Syneos Health

Tier-1/2 CROs

—

Dominant in biotech outsourcing

European mid-size CRO

PSI CRO (Switzerland)

Mid-size

≈ $600M (CCRPS, secondary)

Strong European operational CRO

European mid-size CRO

KCR (Poland)

Mid-size

≈ $200M (CCRPS, secondary)

Competes for the European biotech clients Oxurion seeks

European mid-size CRO

Ergomed (UK)

Mid-size

≈ $250M (CCRPS, secondary)

Overlap in rare disease / oncology

European specialist / early phase

Biotrial (France)

Specialist

≈ $100M (CCRPS, secondary)

French competitor

Biometrics specialist

Cmed (UK)

Specialist

≈ $50M (CCRPS, secondary)

Direct biometrics competitor; much larger

eClinical / CDMS software

Medidata (Dassault Systèmes), Veeva, Oracle, OpenClinica, Ennov, eClinical Solutions

Software

Market leaders (GMI Insights)

Exagis competes as a niche, service-embedded CDMS

MedTech CRO (Eclevar adjacency)

Specialist MedTech CROs (names n/d in sources)

Specialist

—

Eclevar ≈ €2.5M normalised revenue

Peer Comparison FY2025

CompanyRevenue (USD Mn, approx.)Operating marginR&D intensity

Oxurion (FY2025, EUR 0.555M ≈ USD 0.6M)

0.6-593%

324% of revenue

IQVIA

15,000——

ICON

6,500——

PSI CRO

600——

Company Snapshot

1991

Founded

Leuven, Belgium

Headquarters

SWOT Analysis

Strengths

  • Profitable operating asset. Axiodis has been profitable since inception: net result of €12,091 (FY to May 2023), €22,860 (FY to May 2024) and €82,244 (calendar 2025) (AR FY2025 §3.5.1.2).
  • Revenue growth at Axiodis. Operating income rose from €656,650 to €1,003,020 between FY2022/23 and 2025, a cumulative increase of roughly 53%.
  • Proprietary platform. Exagis CDMS is live in operational studies, with eCRF, ePRO, eConsent, SDTM structure and HDS-compliant hosting (H1 2026).
  • Low-cost acquisition model. Axiodis was bought at about 0.7× revenue for €468k. Eclevar is proposed at €1 plus up to €250k of working capital. Both use deferred, performance-linked puts that limit upfront cash.
  • High gross margin on services. H1 2026 gross profit of €584k on €591k of sales (98.8%).
  • Committed (if conditional) funder. Atlas has extended funding repeatedly: amendments in Dec 2023 and Mar 2026, and the loan maturity extension to 31 May 2027.

Weaknesses

  • Negative equity. −€12.7M (FY2025); −€13.3M (H1 2026).
  • Near-zero cash. €31k at 30 Jun 2026 and about €11k on 14 Apr 2026, against a monthly burn of about €0.32M.
  • Client concentration. Top 3 clients ≈ 80% of revenue; largest ≈ 50%.
  • Holding costs exceed revenue. Group G&A of €2.3M (FY2025) is about 4× consolidated revenue.
  • No registered IP. No patents protect the current business (AR FY2025 §3.5.6).
  • Governance gaps. No board committees; a 4-person board with Atlas-proposed directors; multiple Corporate Governance Code deviations.

Opportunities

  • Large, fragmented, growing markets. CRO services projected at a 9.6% CAGR to USD 129.8B by 2029; biostatistics services at a 7.3% CAGR (Roots).
  • MedTech CRO demand under EU MDR. Eclevar has ≈ €2.5M normalised revenue and targets ≈ €3M for FY2027.
  • International CRO LOI. A 75% stake in a target with about 20% EBITDA margin would materially scale group revenue.
  • CRO-to-CRO subcontracting. The KYomed partnership is worth up to €170k a year and is presented as replicable.
  • GLP-1 / peptide / biosimilar programmes. A growing outsourcing pool as key patents expire.
  • Tax losses. €380M of Belgian carry-forwards (end-2023) could shelter future profits, subject to restrictions on use after a merger.

Threats

  • Funding cliff. No financing after 2 March 2027. Atlas tranches depend on market-cap and liquidity conditions; only €1.75M of the planned €3.6M was received in 2025.
  • Dissolution exposure. Net assets have been below €61,500 since 27 Mar 2025, so any interested party may petition for dissolution under BCCA art. 7:229.
  • Extreme dilution. Shares outstanding rose from 88.7M (16 Mar 2026) to 232.0M (Oct 2026). Management states that any prospect of share-value recovery for existing shareholders is remote.
  • Deal-execution risk. Three of five announced acquisition processes have been terminated (stem-cell CRO, French CRO) or remain unconfirmed (international CRO).
  • Reputational contagion to Axiodis. Management itself flags that sponsors may avoid a CRO whose parent carries a going-concern qualification.
  • Atlas control and conflicts. Atlas is presumed to exercise de facto control. It is also lender and pledgee and can block acquisitions under the loan covenants.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
4 Apr 2025AGM postponed; financial calendar amendedReporting slippage
11 Apr 2025FY2024 annual report publishedGoing-concern uncertainty reiterated
17 Apr 2025Share price peaks at €0.10012025 high (AR FY2025)
25 Apr 2025Stem-cell CRO talks terminated; biometrics CRO talks continueFirst M&A setback
13 May 2025AGM votes to continue operations (BCCA art. 7:228) and approves recovery measuresAvoids voluntary dissolution
16 May 2025Binding agreement to acquire 72% of Axiodis for €468kFirst operating asset
12 Jun 2025Axiodis acquisition progressesDeal momentum
10 Jul 2025French Ministry of Economy confirms no FDI review is requiredRegulatory condition lifted
17 Jul 2025Atlas financing secured for Axiodis; closing targeted for 1 AugFunding confirmed
22 Jul 2025€10M indicative crypto-treasury plan with AtlasControversial capital allocation
4 Aug 2025Axiodis acquisition completedBusiness-model pivot executed
4 Aug 2025Improved €30M digital-asset financing offerEscalates crypto plan
7 Aug 2025GA R&D programme ended; refocus on CRO activitiesEnd of the biotech identity
1 Sep 2025Progress on treasury diversification; closing expected before 25 Sep 2025Crypto plan continues
Sep 2025Transparency notification from UBS Group AGHolder disclosure
30 Sep 2025H1 2025 results: net loss €1.19M; cash €6k at 30 Jun 2025Extreme liquidity stress
13 Oct 2025LOI for 80% of a French clinical-development / regulatory CROPipeline deal #2
Dec 2025Binding €30M digital-asset facility reported (secondary: roic.ai)–
19 Jan 2026Crypto financing programme suspended, citing volatility and the macro/geopolitical contextReversal
16 Feb 2026Axiodis accelerates its sales and marketing strategyOrganic growth push
27 Feb 2026French CRO discussions extendedDeal delays
10 Mar 2026Fourth amendment to Atlas funding (to 2 Mar 2027; lighter conditions)Runway extension
16–17 Mar 2026Shares outstanding reach 88,691,312; Atlas holds 20.96%Dilution / control
19 Mar 2026LOI for 75% of an international CROLarger target
7 Apr 2026AGM postponedGovernance slippage
14 Apr 2026Atlas extends the former Kreos/Pontifax loan repayment to 31 May 2027. Share price low of €0.0042; cash about €11kLiquidity crisis
30 Apr 2026FY2025 annual report published; PwC flags material going-concern uncertaintyAudit qualification
1 Jun 2026French CRO deal terminated; international target prioritisedM&A setback #3
1–3 Jun 2026AGM held 1 Jun 2026; results published 3 JunGovernance
2 Jun 2026GLP-1 / peptide / biosimilar offering launched via AxiodisThematic positioning (shares down ≈52% YTD at the time)
21 Jul 2026Axiodis–KYomed INNOV & CEISO biometrics partnershipFirst CRO-to-CRO channel
30 Sep 2026Eclevar exclusive negotiations (68% NewCo, €1 consideration)Pipeline deal #4
30 Sep 2026H1 2026 results: revenue €591k; net loss €0.90M; cash €31kFirst half-year with CRO revenue
8 Oct 2026Updated total voting rights after an Atlas conversion noticeDilution
12–14 Oct 2026Transparency notices: Market Wizards below 3%; Atlas cycles from 0 to 55.6M shares (above 20%) on a 232.0M denominatorShare count up ≈ 2.6× since March 2026

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue / income fell from EUR 1.1 Mn in FY2021 to EUR 0.6 Mn in FY2025.
Oxurion NV — Income Statement: Revenue & Gross Profit
Series (EUR Mn)FY2021FY2022FY2023FY2024FY2025
Revenue / income1.10.60.300.6
Gross profit00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Oxurion NV, Annual Report 2025 — Financial Information (approved 27 Apr 2026; published 30 Apr 2026): oxurion.com/documents/OXUR-Annual-Report-2025-EN-FINAL.pdf
  2. Oxurion NV, Interim Financial Report H1 2026 (30 Sep 2026): oxurion.com/documents/OXUR-GLOBAL-Financial-report-30-06-2026-EN-FINAL.pdf
  3. Oxurion NV, Annual Report 2023 — Financial Information (approved 12 Apr 2024): oxurion.com/documents/ff0038filehref.pdf
  4. Oxurion NV, Annual Report 2021 — Financial Information (approved 24 Mar 2022): oxurion.com/documents/ff0031filehref.pdf
  5. Oxurion NV, Board Report on Statutory Accounts 2024: oxurion.com/documents/OXUR-GLOBAL-Annual-Report-of-the-Board-of-Directors-on-the-statutory-accounts-2024-FINAL.pdf
  6. Oxurion NV, Financial filings index: oxurion.com/investors/shareholder-information/financial-filings
  7. Oxurion NV, Company / Board page: oxurion.com/company
  8. Oxurion press releases via Euronext / Actusnews / FinanzWire / WebDisclosure: opening of GRP (3 Sep 2024); reverse split denominator (9 Sep 2024); share consolidation (25 Jul 2024); board change (14 Feb 2025); termination of 2024 transaction (25 Apr 2025) · Axiodis binding agreement (16 May 2025) · FDI clearance (10 Jul 2025) · Axiodis financing (17 Jul 2025); crypto €10M (22 Jul 2025) · Axiodis completion (4 Aug 2025); crypto €30M (4 Aug 2025) · French CRO LOI (13 Oct 2025); crypto suspension (19 Jan 2026); international CRO LOI (19 Mar 2026) · French CRO termination (1 Jun 2026) · GLP-1 offering (2 Jun 2026) · KYomed partnership (21 Jul 2026) · Eclevar exclusive negotiations (30 Sep 2026) · H1 2026 results (30 Sep 2026); transparency notifications (12 and 14 Oct 2026)
  9. FSMA, Fifth Supplement to the 29 Mar 2023 Prospectus (2024)
  10. Fierce Biotech; pharmaphorum (Nov 2023), on the KALAHARI failure (secondary press)
  11. MarketScreener / Zonebourse quote and company pages (secondary market data)
  12. Simply Wall St: TipRanks/Nasdaq · Craft.co · Stoxray · Google Finance; roic.ai · Whiteford Research Biobase · PharmaSource · ABC Bourse · Option Finance (secondary; flagged where used)
  13. Market sizing: MarketsandMarkets (CRO services) · IntuitionLabs (CRO market share 2026) · Data Bridge Market Research (clinical data management; biostatistics) · MarketIntelo · Roots Analysis · QYResearch via GII · GMI Insights (CDMS vendors) · Towards Healthcare (clinical operations) · CCRPS 2025 CRO directory (peer revenue approximations)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.